<?xml version="1.0" encoding="UTF-8"?><?xml-stylesheet type="text/xsl" href="static/style.xsl"?><OAI-PMH xmlns="http://www.openarchives.org/OAI/2.0/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/ http://www.openarchives.org/OAI/2.0/OAI-PMH.xsd"><responseDate>2026-04-14T04:35:14Z</responseDate><request verb="GetRecord" identifier="oai:www.recercat.cat:2072/479259" metadataPrefix="qdc">https://recercat.cat/oai/request</request><GetRecord><record><header><identifier>oai:recercat.cat:2072/479259</identifier><datestamp>2025-07-29T23:32:35Z</datestamp><setSpec>com_2072_98</setSpec><setSpec>col_2072_378192</setSpec></header><metadata><qdc:qualifieddc xmlns:qdc="http://dspace.org/qualifieddc/" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:dcterms="http://purl.org/dc/terms/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:doc="http://www.lyncode.com/xoai" xsi:schemaLocation="http://purl.org/dc/elements/1.1/ http://dublincore.org/schemas/xmls/qdc/2006/01/06/dc.xsd http://purl.org/dc/terms/ http://dublincore.org/schemas/xmls/qdc/2006/01/06/dcterms.xsd http://dspace.org/qualifieddc/ http://www.ukoln.ac.uk/metadata/dcmi/xmlschema/qualifieddc.xsd">
   <dc:title>Antibiotic Efficacy against Methicillin-Susceptible Staphylococcus aureus Biofilms on Synthetic and Biological Vascular Grafts</dc:title>
   <dc:creator>Tello-Díaz, Cristina</dc:creator>
   <dc:creator>Muñoz, Estela</dc:creator>
   <dc:creator>Palau Gauthier, Marta</dc:creator>
   <dc:creator>Gomis Rodríguez, Javier</dc:creator>
   <dc:creator>Gavaldà, Joan</dc:creator>
   <dc:creator>Gil-Sala, Daniel</dc:creator>
   <dc:creator>Fernández-Hidalgo, Nuria</dc:creator>
   <dc:creator>Bellmunt Montoya, Sergi</dc:creator>
   <dc:subject>Biofilms</dc:subject>
   <dc:subject>Staphylococcus aureus</dc:subject>
   <dc:subject>Vascular graft</dc:subject>
   <dc:subject>Infections</dc:subject>
   <dc:subject>Antibiotics</dc:subject>
   <dcterms:abstract>Background: Biofilm formation is one of the greatest challenges encountered in vascular graft infections. Our aim is to compare the efficacy of 5 antibiotics against methicillin-susceptible Staphylococcus aureus (MSSA) biofilms on the surface of 4 vascular grafts. Methods: In vitro study of 2 clinical MSSA strains (MSSA2 and MSSA6) and 4 vascular grafts (Dacron, Dacron-silver-triclosan (DST), Omniflow-II, and bovine pericardium). After a 24-hr incubation period, the graft samples were divided into 6 groups: growth control (no treatment), ciprofloxacin 4.5 mg/L, cloxacillin 100 mg/L, dalbavancin 300 mg/L, daptomycin 140 mg/L, and linezolid 20 mg/L. Quantitative cultures were obtained and results expressed as log colony-forming units per milliliter (CFU/mL). Analysis of variance was performed to compare biofilm formation between the different groups. Results: The mean ± standard deviation MSSA2 count on the growth control Dacron graft was 10.05 ± 0.31 CFU/mL. Antibiotic treatment achieved a mean reduction of 45%; ciprofloxacin was the most effective antibiotic (64%). Baseline MSSA2 counts were very low on the DST (0.50 ± 1.03 CFU/mL) and Omniflow-II (0.33 ± 0.78 CFU/mL) grafts. On the bovine pericardium patch, the count was 9.87 ± 0.50 CFU/mL, but this was reduced by a mean of 45% after antibiotic treatment (61% for ciprofloxacin). The mean MSSA6 count on the growth control Dacron graft was 9.63 ± 0.53 CFU/mL. Antibiotics achieved a mean reduction of 48%, with ciprofloxacin performing best (67% reduction). The baseline MSSA6 count on the DST graft was 8.54 ± 0.73 CFU/mL. Antibiotics reduced biofilm formation by 72%; cloxacillin was the most effective treatment (86%). The MSSA6 count on the untreated Omniflow-II graft was 1.17 ± 1.52 CFU/mL. For the bovine pericardium patch, it was 8.98 ± 0.67 CFU/mL. The mean reduction after antibiotic treatment was 46%, with cloxacillin achieving the greatest reduction (68%). Conclusions: In this in vitro study, ciprofloxacin and cloxacillin performed best at reducing biofilms formed by clinical MSSA strains on the surface of biological and synthetic vascular grafts.</dcterms:abstract>
   <dcterms:issued>2024</dcterms:issued>
   <dcterms:issued>info:eu-repo/date/embargoEnd/2025-11-30</dcterms:issued>
   <dc:type>Article</dc:type>
   <dc:relation>Annals of Vascular Surgery ; Vol. 108 (November 2024), p. 475-483</dc:relation>
   <dc:rights>embargoed access</dc:rights>
   <dc:rights>Aquest material està protegit per drets d'autor i/o drets afins. Podeu utilitzar aquest material en funció del que permet la legislació de drets d'autor i drets afins d'aplicació al vostre cas. Per a d'altres usos heu d'obtenir permís del(s) titular(s) de drets.</dc:rights>
   <dc:rights>https://rightsstatements.org/vocab/InC/1.0/</dc:rights>
   <dc:publisher/>
</qdc:qualifieddc></metadata></record></GetRecord></OAI-PMH>